[FBIO] Fortress Biotech, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.37 Change: 0.15 (6.76%)
Ext. hours: Change: 0 (0%)

chart FBIO

Refresh chart

Strongest Trends Summary For FBIO

FBIO is in the long-term down -71% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities9.36 M Cash From Investing Activities-1.36 M Cash From Operating Activities-8.83 M Gross Profit
Net Profit-12.06 M Operating Profit-12.07 M Total Assets90.45 M Total Current Assets69.61 M
Total Current Liabilities5.93 M Total Debt24.01 M Total Liabilities30.3 M Total Revenue500 K
Technical Data
High 52 week3.83 Low 52 week0.57 Last close1.9 Last change-1.55%
RSI62.9 Average true range0.19 Beta1.26 Volume144.58 K
Simple moving average 20 days10.34% Simple moving average 50 days7.61% Simple moving average 200 days22.1%
Performance Data
Performance Week6.74% Performance Month30.14% Performance Quart-12.84% Performance Half71.17%
Performance Year-47.8% Performance Year-to-date120.93% Volatility daily6.73% Volatility weekly15.06%
Volatility monthly30.86% Volatility yearly106.89% Relative Volume321.39% Average Volume784.81 K
New High New Low

News

2019-11-12 07:30:00 | Fortress Biotech Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

2019-11-12 07:30:00 | Mustang Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

2019-11-10 09:16:08 | Do Insiders Own Shares In Fortress Biotech, Inc. NASDAQ:FBIO?

2019-11-08 07:30:00 | Checkpoint Therapeutics Announces Presentation of Anti-PD-L1 Cosibelimab Data at the 2019 Society for Immunotherapy of Cancer SITC Annual Meeting

2019-11-07 16:30:00 | Checkpoint Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

2019-11-06 09:15:00 | Mustang Bio Announces MB-107 Lentiviral Gene Therapy and MB-106 CD20-Targeted CAR T Data Selected for Presentations at 61st American Society of Hematology Annual Meeting

2019-11-04 07:30:00 | Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

2019-10-28 08:30:05 | Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development

2019-10-24 08:30:05 | Mustang Bio Announces Dosing of First Participant in Phase 1 Clinical Trial of MB-108 Oncolytic Virus C134 to Treat Glioblastoma

2019-10-24 08:30:05 | Fortress Biotech to Participate in the 5th Annual Dawson James Small Cap Growth Conference

2019-10-18 08:30:05 | Avenue Therapeutics to Present Phase 3 Bunionectomy Study of IV Tramadol at the American Society of Anesthesiologists Annual Meeting

2019-10-10 08:00:00 | Mustang Bio Announces City of Hope Receives $4.1 Million in Grant Awards for Recently Opened First-of-Its-Kind Clinical Trial for Patients with Recurrent Malignant Glioma

2019-09-30 07:30:00 | Checkpoint Therapeutics Announces Presentation of Positive Interim Clinical Results for Anti-PD-L1 Cosibelimab at the European Society for Medical Oncology ESMO Congress 2019

2019-09-26 08:30:00 | Fortress Biotech to Present at October 2019 Investor Conferences

2019-09-26 08:30:00 | Mustang Bio to Participate in October 2019 Investor Conferences

2019-09-26 08:30:00 | Checkpoint Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

2019-09-23 08:30:00 | Mustang Bio Announces Phase 1 Clinical Trial Evaluating MB-105 for Prostate Stem Cell Antigen-Positive Castration-Resistant Prostate Cancer Enrolling Patients at City of Hope

2019-09-16 07:30:00 | Checkpoint Therapeutics Announces Data Presentation at the European Society for Medical Oncology ESMO Congress 2019

2019-09-11 13:20:34 | Investors Who Bought Fortress Biotech NASDAQ:FBIO Shares Three Years Ago Are Now Down 24%

2019-09-09 08:00:00 | Mustang Bio to Present at Scientific Conferences in September 2019

2019-09-04 08:30:00 | Checkpoint Therapeutics to Present at September 2019 Investor Conferences

2019-08-29 08:00:00 | Mustang Bio to Present at September 2019 Investor Conferences

2019-08-27 11:42:12 | A Look At Benzinga Pro's Most-Searched Tickers For August 27, 2019

2019-08-27 08:00:00 | Mustang Bio Announces License Agreement with CSL Behring for the Cytegrity™ Stable Producer Cell Line for the Production of MB-107 Lentiviral Gene Therapy

2019-08-26 11:49:02 | A Look At Benzinga Pro's Most-Searched Tickers For August 26, 2019

2019-08-22 08:00:00 | Mustang Bio and St. Jude Children’s Research Hospital announce MB-107 lentiviral gene therapy for X-linked Severe Combined Immunodeficiency XSCID granted regenerative medicine advanced therapy RMAT designation from FDA

2019-08-19 08:00:00 | Fortress Biotech Announces Appointment of Kevin L. Lorenz, J.D., to Board of Directors

2019-08-14 07:30:00 | Avenue Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights

2019-08-13 08:00:00 | Mustang Bio Announces $9.28 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-103 in HER2-Positive Breast Cancer with Brain Metastases

2019-08-09 16:05:00 | Fortress Biotech Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights

2019-08-09 16:05:00 | Mustang Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights

2019-08-08 16:30:00 | Checkpoint Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights

2019-08-05 08:00:00 | FDA Clears IND for Mustang Bio’s MB-102 CD123 CAR T

2019-08-01 08:00:00 | Avenue Therapeutics Announces Appointment of Ms. E. Garrett Ingram to Board of Directors

2019-07-24 08:00:00 | Mustang Bio Receives Orphan Drug Designation for MB-102 CD123 CAR T for the Treatment of Acute Myeloid Leukemia

2019-07-12 10:13:21 | Have Insiders Been Selling Fortress Biotech, Inc. NASDAQ:FBIO Shares?

2019-07-01 08:30:00 | Checkpoint Therapeutics Added to Russell 2000® Index

2019-06-03 07:00:00 | Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain

2019-05-23 08:30:00 | Mustang Bio and St. Jude Children’s Research Hospital to Participate in Panel Discussion at Boston CEO 2019

2019-05-17 09:35:01 | Will Fortress Biotech to Surge Higher?

2019-05-16 08:00:00 | Mustang Bio and Nationwide Children’s Hospital Receive Orphan Drug Designation for MB-108 Oncolytic Virus C134 for the Treatment of Malignant Glioma

2019-05-13 08:00:00 | Mustang Bio to Present at the Cell & Gene Therapy USA Congress 2019

2019-05-13 07:30:00 | Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights

2019-05-10 07:44:32 | Fortress Biotech: 1Q Earnings Snapshot

2019-05-10 07:30:00 | Fortress Biotech Reports First Quarter 2019 Financial Results and Recent Corporate Highlights

2019-05-09 17:00:00 | Checkpoint Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights

2019-05-08 09:25:00 | Mustang Bio Announces Full Exercise of Option

2019-05-08 07:30:00 | Mustang Bio Announces City of Hope Opens First-of-Its-Kind Multiple Myeloma CAR T Cell Therapy Trial Targeting CS1 Protein

2019-05-01 07:30:00 | Checkpoint Therapeutics Announces Positive Interim Clinical Results of Anti-PD-L1 Antibody Cosibelimab

2019-04-30 07:30:00 | Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors